金斯瑞生物科技(01548.HK):在傳奇開曼持股攤薄至76.9%
格隆匯4月16日丨金斯瑞生物科技(01548.HK)宣佈,於2020年4月16日,購買協議所載有關額外完成的所有先決條件已達成,Rising Arrow Enterprise Ltd(額外買方)進行的額外購買事項已完成。
額外完成時,傳奇開曼向額外買方發行128.34萬股額外A類優先股,總對價約1000萬美元。額外完成時,額外買方作為額外參與方簽訂投資者權利協議及優先購買權和共同銷售協議。同日,額外買方與公司簽訂額外擔保協議。傳奇開曼亦於額外完成時根據經重述章程向額外買方授予贖回權。
額外完成後,傳奇開曼由公司持有約76.9%股份,由Aqua Point持有約13.7%股份,由買方(包括額外買方)持有約9.3%股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.